Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senators Fear Viral Spread Of Gilead Pricing Strategy

This article was originally published in Scrip

Executive Summary

While it was Gilead Sciences Inc.'s hepatitis C virus (HCV) treatments Sovaldi (sofosbuvir) and Harvoni (ledipasvir-sofosbuvir) that was at the center of a bipartisan congressional investigation into how the company priced those drugs, the concern by the lawmakers who initiated the probe was what would happen if the company's approach is adopted by other firms selling blockbuster specialty medicines for Alzheimer's, cancer, diabetes and HIV.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel